Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants

Expert Review of Vaccines

Volumn 14, Issue 12, 2015, Pages 1651-1660

  Dangor, Ziyaad ^a   Kwatra, Gaurav ^a   Izu, Alane ^a   Adrian, Peter ^a   Cutland, Clare L ^a   Velaphi, Sithembiso ^a   Ballot, Daynia ^a   Reubenson, Gary ^a   Zell, Elizabeth R ^b   Lala, Sanjay G ^a   Madhi, Shabir A ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Stat Epi Assoc Inc   (United States)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

BibA; FbsA; GBS; Group B Streptococcus; Pilus island; Streptococcus agalactiae

Indexed keywords

BACTERIAL PROTEIN; FIBRINOGEN BINDING PROTEIN A; GROUP B STREPTOCOCCUS SURFACE IMMUNOGENIC BACTERIAL ADHESIN; GROUP B STREPTOCOCCUS SURFACE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MATERNAL ANTIBODY; MEMBRANE PROTEIN; PILUS ISLAND 1 PROTEIN; PILUS ISLAND 2A PROTEIN; PILUS ISLAND 2B PROTEIN; UNCLASSIFIED DRUG; ADHESIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; MEMBRANE ANTIGEN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BIRTH WEIGHT; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; GROUP B STREPTOCOCCAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFANT; INFANT DISEASE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PREGNANT WOMAN; PRIORITY JOURNAL; RISK FACTOR; BLOOD; FIMBRIA; IMMUNOLOGY; MICROBIOLOGY; NEWBORN; RISK; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; CASE-CONTROL STUDIES; FEMALE; FIMBRIAE, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; RISK; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84947047648     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1085307     Document Type: Article

References (26)

1. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011;30(11):937-41
2. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011;364(21):2016-25
3. Okike IO, Johnson AP, Henderson KL, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United kingdom and republic of ireland: prospective, enhanced, national population-based surveillance. Infec Dis Soc Am 2014;59(10):e150-7
4. Dangor Z, Kwatra G, Izu A, et al. Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants. Exp Rev Vacc 2015;14(1):135-49
5. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of earlyand late-onset invasive disease in young-infants. Vaccine 2013;31(Suppl 4): D52-7
6. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. The Lancet 2012;379(9815):547-56
7. Lindahl G, Stalhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 2005;18(1):102-27
8. Meinke AL, Senn BM, Visram Z, et al. Immunological fingerprinting of group B streptococci: from circulating human antibodies to protective antigens. Vaccine 2010;28(43):6997-7008
9. Lachenauer CS, Baker CJ, Baron MJ, et al. Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. J Infec Dis 2002;185(3): 368-74
10. Manning SD, Wood S, Kasha K, et al. Naturally occurring antibodies for the group B streptococcal surface immunogenic protein (Sip) in pregnant women and newborn babies. Vaccine 2006;24(47-48): 6905-12
11. Larsson C, Lindroth M, Nordin P, et al. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection. Arch Dis Child Fetal Neonatal Ed 2006;91(6):F403-8
12. Pannaraj PS, Kelly JK, Madoff LC, et al. Group B Streptococcus bacteremia elicits beta C protein-specific IgMand IgG in humans. J Infec Dis 2007;195(3):353-6
13. Pannaraj PS, Kelly JK, Rench MA, et al. Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine 2008;26(4):502-8
14. Rajagopal L. Understanding the regulation of Group B Streptococcal virulence factors. Future Microbiol 2009;4(2):201-21
15. Martins ER, Andreu A, Melo-Cristino J, Ramirez M. Distribution of pilus islands in Streptococcus agalactiae that cause human infections: insights into evolution and implication for vaccine development. CVI 2013;20(2):313-16
16. Dangor Z, Lala SG, Cutland CL, et al. Burden of invasive Group B Streptococcus disease and early neurological sequelae in South African infants. PloS One 2015
17. Kwatra G, Adrian PV, Shiri T, et al. Serotype-specific acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy. PLoS One 2014;9(6):e98778
18. Madzivhandila M, Adrian PV, Cutland CL, et al. Distribution of pilus islands of group B streptococcus associated with maternal colonization and invasive disease in South Africa. J Med Microbiol 2013;62(Pt 2): 249-53
19. Dangor Z, Kwatra G, Izu A, et al. HIV-1 is associated with lower Group B Streptococcus capsular and surface-protein IgG antibody levels and reduced transplacental antibody transfer in pregnant women. J Infec Dis 2015
20. Kleinbaum Dg, Klein M. Logistic regression, a self-learning text. Springer; New York: 2002. p. 245-7
21. Carey V, Baker C, Platt R. Bayesian inference on protective antibody levels using case-control data. Biometrics 2001;57(1): 135-42
22. Plummer M. JAGS: A Program for Analysis of Bayesian Graphical Models Using Gibbs Sampling. JAGS 2003
23. Papasergi S, Lanza Cariccio V, Pietrocola G, et al. Immunogenic properties of Streptococcus agalactiae FbsA fragments. PLoS One 2013;8(9):e75266
24. Santi I, Maione D, Galeotti CL, et al. BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. J Infect Dis 2009;200(4): 564-70
25. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 2005;309(5731):148-50
26. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infec Dis 2009; 199(1):108-15